The Sodium Dependent Serotonin Transporter pipeline drugs market research report outlays comprehensive information on the Sodium Dependent Serotonin Transporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sodium Dependent Serotonin Transporter pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Women’s Health, Genetic Disorders, and Musculoskeletal Disorders which include the indications Depression, Major Depressive Disorder, Female Sexual Dysfunction, Vasomotor Symptoms of Menopause (Hot Flashes), Prader-Willi Syndrome (PWS), Unspecified Genetic Disorders, and Osteoarthritis. It also reviews key players involved in Sodium Dependent Serotonin Transporter targeted therapeutics development with respective active and dormant or discontinued products.
The Sodium Dependent Serotonin Transporter pipeline targets constitutes close to 43 molecules. Out of which, approximately 38 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 1, 1, 9, 13, 6, 2, and 6 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 2, and 1 molecule.
Sodium Dependent Serotonin Transporter overview
The sodium-dependent serotonin transporter (SERT) is a protein that cotransports serotonin with one Na+ ion in exchange for one K+ ion and possibly one proton in an overall electroneutral transport cycle. SERT transports serotonin across the plasma membrane from the extracellular compartment to the cytosol, thus limiting serotonin intercellular signaling.
For a complete picture of Sodium Dependent Serotonin Transporter’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
